Current and emerging treatments for the management of myasthenia gravis

Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate,...

Descripción completa

Detalles Bibliográficos
Autor principal: Sathasivam, Sivakumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150477/
https://www.ncbi.nlm.nih.gov/pubmed/21845054
http://dx.doi.org/10.2147/TCRM.S14015
_version_ 1782209553900765184
author Sathasivam, Sivakumar
author_facet Sathasivam, Sivakumar
author_sort Sathasivam, Sivakumar
collection PubMed
description Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term immunomodulation (thymectomy). This review explores in detail these different treatment options. Potential future treatments are also discussed.
format Online
Article
Text
id pubmed-3150477
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31504772011-08-15 Current and emerging treatments for the management of myasthenia gravis Sathasivam, Sivakumar Ther Clin Risk Manag Review Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term immunomodulation (thymectomy). This review explores in detail these different treatment options. Potential future treatments are also discussed. Dove Medical Press 2011 2011-07-22 /pmc/articles/PMC3150477/ /pubmed/21845054 http://dx.doi.org/10.2147/TCRM.S14015 Text en © 2011 Sathasivam, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Sathasivam, Sivakumar
Current and emerging treatments for the management of myasthenia gravis
title Current and emerging treatments for the management of myasthenia gravis
title_full Current and emerging treatments for the management of myasthenia gravis
title_fullStr Current and emerging treatments for the management of myasthenia gravis
title_full_unstemmed Current and emerging treatments for the management of myasthenia gravis
title_short Current and emerging treatments for the management of myasthenia gravis
title_sort current and emerging treatments for the management of myasthenia gravis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150477/
https://www.ncbi.nlm.nih.gov/pubmed/21845054
http://dx.doi.org/10.2147/TCRM.S14015
work_keys_str_mv AT sathasivamsivakumar currentandemergingtreatmentsforthemanagementofmyastheniagravis

Ejemplares similares